Skip to main content
Caplight Logo









Ustar Biotechnologies (Hangzhou) Ltd.

Ustar Biotechnologies (Hangzhou) Ltd.

Private
HangzhouHealthcare & Life Scienceshttps://www.bioustar.com/

Last Round

Series E

Extension

Nov 30, 2021

Total Funding Raised

$78M

Company Overview

Ustar Biotechnologies (Hangzhou) Ltd. is a life sciences company that develops and manufactures innovative point-of-care molecular diagnostic instruments and test kits for infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Biotech Equipment

Business Model

B2B

Customer Profile

Usage-Based SaaS, Hardware Sales

AI Layer

Non-AI

Keywords

point-of-care diagnosticsPOCmolecular diagnosticsisothermal amplificationnucleic acid testingNATmultiplex PCRdiagnostic cartridgespathogen detectionbedside testingrazor-and-blade modelreagent stabilizationrapid diagnosticsclinical laboratory equipmentin-vitro diagnosticsIVD

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ustar Biotechnologies (Hangzhou) Ltd. Comparables

Compare Ustar Biotechnologies (Hangzhou) Ltd. with similar companies based on industry and business-model similarity.

Ustar Biotechnologies (Hangzhou) Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Guangzhou Pluslife Biotech Co., Ltd.
89%
Igenesis
85%
Molbio Diagnostics
84%

Ustar Biotechnologies (Hangzhou) Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series E ExtensionNov 30, 2021
Series EFeb 19, 2021
Series DJun 27, 2018

Ustar Biotechnologies (Hangzhou) Ltd. Investors

Notable investors and investment history

Ustar Biotechnologies (Hangzhou) Ltd. investors
InvestorRounds
Oriental Fortune CapitalSeries E Extension, Series E
Cenova CapitalSeries E
CPESeries E Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 30, 2021

    $47M round led by CPE

  • Feb 19, 2021

    $31M round led by Oriental Fortune Capital

Ustar Biotechnologies (Hangzhou) Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ustar Biotechnologies (Hangzhou) Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ustar Biotechnologies (Hangzhou) Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Employee Range34
Year Founded2005
Last FundingNov 30, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?